论文部分内容阅读
阿霉素(Adriamycin,ADR)属蒽环素类行生物,是一种广谱抗肿瘤药物,已被广泛应用治疗实质性及血液系统恶性肿瘤。但因明显的心脏毒性而使其应用受限。ADR引起心肌病的发生率为1.7～6.8％。其中最重要的危险因素是药物的累积量。VonHoff等回顾性研究3941例用阿霉素患者表明:药物总量与心力衰竭发生率之间具有相关性。当ADR剂量分别为400mg/m~2、550mg/m~2及700mg/m~2时,心力衰竭的发生率分别为3％、7％
Adriamycin (ADR) is an anthracycline bioenzyme. It is a broad-spectrum antitumor drug and has been widely used to treat substantial and hematologic malignancies. However, its use is limited due to obvious cardiotoxicity. The incidence of ADR-induced cardiomyopathy was 1.7 to 6.8%. The most important risk factor is the cumulative amount of the drug. VonHoff and other retrospective studies of 3941 patients with adriamycin showed that there was a correlation between the total drug amount and the incidence of heart failure. When the doses of ADR were 400mg/m~2, 550mg/m~2 and 700mg/m~2 respectively, the incidence of heart failure was 3% and 7% respectively.